The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

BACKGROUND: Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. METHODS: To assess the efficacy and safety of CAR T therapy, we analyzed clinical trials from PUBMED and EMBASE. RESULTS: Results showe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hui, Luo, Yuling, Zhu, Sha, Wang, Xi, Zhao, Yunuo, Ou, Xuejin, Zhang, Tao, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158876/
https://www.ncbi.nlm.nih.gov/pubmed/30257649
http://dx.doi.org/10.1186/s12885-018-4817-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158876/
https://www.ncbi.nlm.nih.gov/pubmed/30257649
http://dx.doi.org/10.1186/s12885-018-4817-4

Ejemplares similares